CLINICAL DURABILITY OF THE PERICARDIAL XENOGRAFT VALVE - 10 YEARS EXPERIENCE WITH MITRAL REPLACEMENT
CLINICAL DURABILITY OF THE PERICARDIAL XENOGRAFT VALVE - 10 YEARS EXPERIENCE WITH MITRAL REPLACEMENT
复制标题
DOI：
10.1016/s0003-4975(10)62496-4
复制
发表时间：
1982-01-01
影响因子：
4.6
通讯作者：
TANDON, AP
中科院分区：
文献类型：
--
作者：
IONESCU, MI;SMITH, DR;TANDON, AP
Data from 366 patients with mitral valve replacement (250 single and 116 multiple) who received pericardial xenografts between 1971 and 1981 were analyzed. Cumulative duration of follow-up was 1151 patient-yr, with a maximum duration of 10.7 yr. Actuarial survival at 11 yr is 71.6 .+-. 14.2%. Pericardial valve failure occurred in 7 patients (0.6 episodes/100 patient-yr). Actuarial freedom from valve failure at 1 yr is 90.4 .+-. 9.1% for the entire series. Although 275 (75.1%) patients were in chronic atrial fibrillation, anticoagulants were not used in any patient beyond the first 6 postoperative weeks. The incidence of emboli was 0.6%/yr. Six episodes occurred following single mitral valve replacement and 1 after multiple valve replacement (5 early and 2 late). The actuarial freedom from embolism is 96.4 .+-. 1.5% at 6 and 11 yr postoperatively. Valve thrombosis was not encountered. This analysis has shown a low incidence of valve dysfunction and a very low risk of embolic complications without long-term anticoagulation. The pericardial xenograft is a safe substitute for the mitral valve, with predictable behavior during the 1st decade of follow-up.
